Asperentin B, a new inhibitor of the protein tyrosine phosphatase 1B

33Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

In the frame of studies on secondary metabolites produced by fungi from deep-sea environments we have investigated inhibitors of enzymes playing key roles in signaling cascades of biochemical pathways relevant for the treatment of diseases. Here we report on a new inhibitor of the human protein tyrosine phosphatase 1B (PTP1B), a target in the signaling pathway of insulin. A new asperentin analog is produced by an Aspergillus sydowii strain isolated from the sediment of the deep Mediterranean Sea. Asperentin B (1) contains an additional phenolic hydroxy function at C-6 and exhibits an IC50 value against PTP1B of 2 μM in vitro, which is six times stronger than the positive control, suramin. Interestingly, asperentin (2) did not show any inhibition of this enzymatic activity. Asperentin B (1) is discussed as possible therapeutic agents for type 2 diabetes and sleeping sickness.

Cite

CITATION STYLE

APA

Wiese, J., Aldemir, H., Schmaljohann, R., Gulder, T. A. M., Imhoff, J. F., & Kerr, R. (2017). Asperentin B, a new inhibitor of the protein tyrosine phosphatase 1B. Marine Drugs, 15(6). https://doi.org/10.3390/md15060191

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free